ZUMA-7 Axi-Cel Superiority Calls for Treatment Paradigm Shift in R/R LBLC

Article

The analysis of data from ZUMA-7 demonstrated significant efficacy for axi-cel over second-line standard treatment.

Data from ZUMA-7, a multicenter phase 3 trial, demonstrated statistically significant and clinically relevant improvements in event-free survival (EFS) and response rates in patients with relapsed/refractory large B-cell lymphoma (LBLC) treated with axicabtageneciloleucel (axi-cel) versus second-line standard of care (SOC) chemoimmunotherapy.

The findings, presented at the Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR (2022 Tandem Meetings), held in Salt Lake City, Utah, and virtually April 23-26, 2022, suggest that axi-cel should be considered second-line SOC for r/r LBLC.

The data presented included findings from 359 patients who were randomly assigned to receive either axi-cel (n=180) or SOC (n=179). Participants, of whom 74% had primary refractory disease, had a median age of 59. The primary end point was event-free survival, and secondary end points included objective response rate and overall survival.

Treatment with axi-cel met the primary end point, with EFS significantly longer at 24.9 months in the axi-cel group compared with SOC (8.3 months vs 2 months, P <.0001). In addition, EFS Kaplan-Meier estimates were 41% and 16%, respectively, and objective response rates (ORR) and complete response (CR) rates were higher in the axi-cel group compared with SOC (ORR: 83% vs 50%, odds ratio: 5.31 [95% CI, 3.1-8.9; P <.0001]; CR: 65% vs 32%). Median overall survival, evaluated as an interim analysis, was not reached for axi-cel vs 35.1 months for SOC (HR 0.730; P=.027). Notably 56% of patients in the SOC arm received crossover treatment with axi-cel off-protocol.

Progression-free survival (PFS) was also superior in the axi-cel group, with median PFS 14.7 months in the axi-cel cohort compared with 3.7 months in the SOC cohort.

“This intent to treat PFS curve compares favorably to the modified intent to treat PFS curve from ZUMA-1, suggesting that efficacy of axi-cel in a second line setting may be superior to efficacy seen in a third or later line,” primary investigator Frederick Locke, MD, of Moffitt Cancer Center, said during the data presentation.

In terms of safety, 91% (axi-cel) and 83% (SOC) of patients reported Grade 3 or higher treatment-emergent adverse events (TEAEs), with 1 and 2 patient treatment-related deaths occurring in each group, respectively. Grade 3 or higher cytokine release syndrome and neurologic events ccurred in 6% and 21% of the axi-cel group, with no grade 5 events recorded.

Notably, of the 180 participants randomized to axi-cel, 170 (94%) ultimately received definitive therapy compared with 36% of the SOC arm.

Overall, axi-cel demonstrated a more than 4-fold greater median EFS, 2.5-fold greater 2-year EFS, and 2-fold greater CR rate compared with SOC.

REFERENCE
Locke FL, Miklos DB, Perales MA, et al. Primary Analysis of Zuma‑7: A Phase 3 Randomized Trial of AxicabtageneCiloleucel (Axi-Cel) Versus Standard‑of‑Care (SOC) Therapy in Patients with Relapsed/Refractory Large B-Cell Lymphoma. Presented at: Presented at: the 2022 Transplantation & Cellular Therapy Meetings; Salt Lake City, UT; April 23-26, 2022.
Recent Videos
Arun Upadhyay, PhD, the chief scientific officer and head of research, development, and Medical at Ocugen
Arun Upadhyay, PhD, the chief scientific officer and head of research, development, and Medical at Ocugen
Barry J. Byrne, MD, PhD, the chief medical advisor of Muscular Dystrophy Association (MDA) and a physician-scientist at the University of Florida
John Brandsema, MD, a pediatric neurologist in the Division of Neurology at Children’s Hospital of Philadelphia
Chun-Yu Chen, PhD, a research scientist at Seattle Children’s Research Institute
Alexandra Collin de l’Hortet, PhD, the head of therapeutics at Epic Bio
David Dimmock, MBBS, on Accelerating Therapy Discovery and Approval With AI David Dimmock, MBBS, on Accelerating Therapy Discovery and Approval With AI
John Finn, PhD, the chief scientific officer of Tome Biosciences
David Dimmock, MBBS, on a Promising Case Study of Ultra-Rare, AI-Guided, ASO Development
Scott Jeffers, PhD, on The Importance of Precise Reproducibility of AAVs
Related Content
© 2024 MJH Life Sciences

All rights reserved.